Swiss drugmaker Roche Holding (ROG.S), opens new tab plans to investigate whether an experimental medicine can delay or prevent Alzheimer’s disease symptoms, it said on Sunday, as a part of the company’s growing development programme for the disease.
The clinical trial of the drug, Trontinemab, will target people who are at risk of cognitive decline and will aim to delay or prevent the symptoms of Alzheimer’s, Roche said in a statement.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
Trontinemab is designed so that the drug is transported across the blood brain barrier—protective blood vessels that prevent chemicals in the bloodstream from entering the brain — in hopes of delivering more of the treatment to the brain.
Rivals like Eli Lilly (LLY.N), opens new tab have been making progress in the complicated field of Alzheimer’s recently, with Lilly’s drug Kisunla getting a recommendation for approval for certain patients from the European Medicines Agency last week. Kisunla is already approved in the U.S.
Treatments for Alzheimer’s approved so far, including Eisai (4523.T), opens new tab and Biogen’s (BIIB.O), opens new tab Leqembi and Lilly’s Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain.
